Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
45
XNCR Quote, Financials, Valuation and Earnings
Last price:
$11.02
Seasonality move
:
15.21%
Day range:
$10.30 - $10.90
52-week range:
$7.16 - $27.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.23x
P/B ratio:
1.10x
Volume:
540.9K
Avg. volume:
949.2K
1-year change:
-49.79%
Market cap:
$745.5M
Revenue:
$110.5M
EPS (TTM):
-$3.63
Analysts' Opinion
-
Consensus RatingXencor has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.30, Xencor has an estimated upside of 186.39% from its current price of $10.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $10.58.
Fair Value
-
According to the consensus of 8 analysts, Xencor has 186.39% upside to fair value with a price target of $30.30 per share.
XNCR vs. S&P 500
-
Over the past 5 trading days, Xencor has underperformed the S&P 500 by -2.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xencor does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xencor has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Xencor reported revenues of $52.8M.
Earnings Growth
-
Xencor has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xencor reported earnings per share of -$0.62.
Enterprise value:
407.7M
EV / Invested capital:
--
Price / LTM sales:
6.23x
EV / EBIT:
--
EV / Revenue:
3.69x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-1.93x
Price / Operating cash flow:
37.37x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-25.22%
Net Income Margin (TTM):
-210.53%
Return On Equity:
-35.99%
Return On Invested Capital:
-31.93%
Operating Margin:
-24.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $164.6M | $174.6M | $110.5M | $51M | $52.8M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$82.5M | -$132.4M | -$178.4M | -$27.4M | -$13.2M | |
| EBITDA | -$45.7M | -$102M | -$186.2M | -$3.3M | -$32.9M | |
| Diluted EPS | -$0.93 | -$2.10 | -$3.63 | -$0.31 | -$0.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $637.7M | $424.4M | $675.3M | $635.6M | $577.6M | |
| Total Assets | $703.2M | $838.2M | $846.3M | $965.1M | $951.9M | |
| Current Liabilities | $121.1M | $70.7M | $63.8M | $73.9M | $87.4M | |
| Total Liabilities | $130.8M | $104.7M | $118.8M | $303M | $277.9M | |
| Total Equity | $572.4M | $733.5M | $727.5M | $662.1M | $674M | |
| Total Debt | -- | -- | -- | $189.5M | $163.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.5M | -$77.9M | -$202.2M | $18.2M | -$49.8M | |
| Cash From Investing | -$119.7M | -$111.1M | -$7.9M | -$203.1M | $57.3M | |
| Cash From Financing | $5.7M | $189.2M | $197.2M | $186M | $4.4M | |
| Free Cash Flow | -$18.9M | -$99.2M | -$211.7M | $16.5M | -$52.5M | |
XNCR
Sector
Market Cap
$745.5M
$34.9M
Price % of 52-Week High
38.84%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-49.79%
-38.5%
Beta (5-Year)
0.900
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.54
200-day SMA
Sell
Level
$18.56
Bollinger Bands (100)
Sell
Level
11.3 - 22.7
Chaikin Money Flow
Buy
Level
10.5M
20-day SMA
Buy
Level
$9.54
Relative Strength Index (RSI14)
Sell
Level
49.08
ADX Line
Buy
Level
37.09
Williams %R
Neutral
Level
-35.1044
50-day SMA
Sell
Level
$12.07
MACD (12, 26)
Sell
Level
-0.37
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
29.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4967)
Sell
CA Score
(Annual)
Level (-0.441)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.5257)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Stock Forecast FAQ
In the current month, XNCR has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XNCR average analyst price target in the past 3 months is $30.30.
-
Where Will Xencor Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xencor share price will rise to $30.30 per share over the next 12 months.
-
What Do Analysts Say About Xencor?
Analysts are divided on their view about Xencor share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xencor is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Xencor's Price Target?
The price target for Xencor over the next 1-year time period is forecast to be $30.30 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XNCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xencor is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XNCR?
You can purchase shares of Xencor via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xencor shares.
-
What Is The Xencor Share Price Today?
Xencor was last trading at $11.02 per share. This represents the most recent stock quote for Xencor. Yesterday, Xencor closed at $10.58 per share.
-
How To Buy Xencor Stock Online?
In order to purchase Xencor stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
